Whitener Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2M | Sell |
82,959
-4,143
| -5% | -$108K | 0.42% | 53 |
|
|
2026
Q1 | $2.45M | Buy |
87,102
+3,252
| +4% | +$86.6K | 0.56% | 44 |
|
|
2025
Q4 | $2.09M | Buy |
83,850
+4,726
| +6% | +$119K | 0.48% | 45 |
|
|
2025
Q3 | $2.02M | Buy |
79,124
+4,035
| +5% | +$99.6K | 0.48% | 44 |
|
|
2025
Q2 | $1.82M | Buy |
75,089
+2,476
| +3% | +$57.7K | 0.48% | 47 |
|
|
2025
Q1 | $1.84M | Sell |
72,613
-2,177
| -3% | -$57K | 0.52% | 47 |
|
|
2024
Q4 | $1.98M | Buy |
74,790
+22,145
| +42% | +$601K | 0.56% | 42 |
|
|
2024
Q3 | $1.52M | Buy |
52,645
+20,250
| +63% | +$591K | 0.43% | 55 |
|
|
2024
Q2 | $906K | Sell |
32,395
-3,305
| -9% | -$91K | 0.27% | 71 |
|
|
2024
Q1 | $991K | Buy |
35,700
+1,181
| +3% | +$32.8K | 0.32% | 66 |
|
|
2023
Q4 | $994K | Sell |
34,519
-13,660
| -28% | -$413K | 0.36% | 59 |
|
|
2023
Q3 | $1.6M | Sell |
48,179
-582
| -1% | -$20.6K | 0.64% | 38 |
|
|
2023
Q2 | $1.79M | Sell |
48,761
-1,016
| -2% | -$39.5K | 0.69% | 36 |
|
|
2023
Q1 | $2.03M | Sell |
49,777
-1,258
| -2% | -$54.3K | 0.85% | 31 |
|
|
2022
Q4 | $2.62M | Sell |
51,035
-70
| -0.1% | -$3.36K | 1.14% | 25 |
|
|
2022
Q3 | $2.24M | Buy |
51,105
+800
| +2% | +$38.9K | 1.06% | 25 |
|
|
2022
Q2 | $2.64M | Sell |
50,305
-1,910
| -4% | -$97.3K | 1.19% | 22 |
|
|
2022
Q1 | $2.7M | Buy |
52,215
+905
| +2% | +$47K | 1.02% | 25 |
|
|
2021
Q4 | $3.03M | Buy |
51,310
+11,636
| +29% | +$577K | 1.08% | 24 |
|
|
2021
Q3 | $1.46M | Sell |
39,674
-9,966
| -20% | -$442K | 0.67% | 40 |
|
|
2021
Q2 | $1.94M | Buy |
49,640
+2,437
| +5% | +$94.8K | 0.77% | 34 |
|
|
2021
Q1 | $1.71M | Buy |
47,203
+7,529
| +19% | +$267K | 0.74% | 34 |
|
|
2020
Q4 | $1.46M | Buy |
39,674
+33
| +0.1% | +$1.21K | 0.67% | 40 |
|
|
2020
Q3 | $1.38M | Buy |
39,641
+10,466
| +36% | +$367K | 0.66% | 42 |
|
|
2020
Q2 | $905K | Buy |
29,175
+158
| +0.5% | +$5.37K | 0.47% | 55 |
|
|
2020
Q1 | $898K | Buy |
29,017
+838
| +3% | +$28.6K | 0.58% | 48 |
|
|
2019
Q4 | $1.05M | Buy |
28,179
+1,015
| +4% | +$36.2K | 0.54% | 49 |
|
|
2019
Q3 | $925K | Buy |
27,164
+74
| +0.3% | +$2.69K | 0.51% | 48 |
|
|
2019
Q2 | $1.11M | Buy |
27,090
+1,603
| +6% | +$63.7K | 0.63% | 43 |
|
|
2019
Q1 | $1.03M | Buy |
25,487
+4,579
| +22% | +$183K | 0.67% | 40 |
|
|
2018
Q4 | $865K | Buy |
20,908
+616
| +3% | +$25.6K | 0.64% | 43 |
|
|
2018
Q3 | $848K | Buy |
20,292
+317
| +2% | +$12.2K | 0.56% | 49 |
|
|
2018
Q2 | $687K | Sell |
19,975
-291
| -1% | -$9.94K | 0.54% | 56 |
|
|
2018
Q1 | $682K | Buy |
20,266
+2,550
| +14% | +$87.7K | 0.52% | 55 |
|
|
2017
Q4 | $608K | Buy |
+17,716
| New | +$604K | 0.52% | 56 |
|
Other funds holding PFE
Whitener Capital Management's PFE Position: Q2 2026 in Review
Whitener Capital Management reduced its Pfizer (PFE) stake by 4.8% in Q2 2026, selling an estimated $108K and leaving 82,959 shares worth $2M. The position accounts for 0.42% of the portfolio, ranked #53.
Whitener Capital Management first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.03M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Whitener Capital Management held 82,959 shares of Pfizer worth $2M as of Q2 2026.
- Whitener Capital Management sold 4,143 Pfizer shares in Q2 2026, an estimated $108K.
- Pfizer made up 0.42% of Whitener Capital Management's portfolio in Q2 2026, its #53 holding.
- Whitener Capital Management first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Whitener Capital Management's Pfizer position peaked at $3.03M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Whitener Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.